Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction

Abstract

Background Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Up to 20%–30% of patients hospitalized with COVID-19 have evidence of cardiac dysfunction. Xuebijing injection is a compound injection containing five traditional Chinese medicine ingredients, which can protect cells from SARS-CoV-2-induced cell death and improve cardiac function. However, the specific protective mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction remains unclear. Methods The therapeutic effect of Xuebijing injection on COVID-19 was validated by the TCM Anti COVID-19 (TCMATCOV) platform. RNA-sequencing (RNA-seq) data from GSE150392 was used to find differentially expressed genes (DEGs) from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) infected with SARS-CoV-2. Data from GSE151879 was used to verify the expression of Angiotensin I Converting Enzyme 2 (ACE2) and central hub genes in both human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) and adult human CMs with SARS-CoV-2 infection. Results A total of 97 proteins were identified as the therapeutic targets of Xuebijing injection for COVID-19. There were 22 DEGs in SARS-CoV-2 infected hiPSC-CMs overlapped with the 97 therapeutic targets, which might be the therapeutic targets of Xuebijing injection on COVID-19-induced cardiac dysfunction. Based on the bioinformatics analysis, 7 genes (CCL2, CXCL8, FOS, IFNB1, IL-1A, IL-1B, SERPINE1) were identified as central hub genes and enriched in pathways including cytokines, inflammation, cell senescence and oxidative stress. ACE2, the receptor of SARS-CoV-2, and the 7 central hub genes were differentially expressed in at least two kinds of SARS-CoV-2 infected CMs. Besides, FOS and quercetin exhibited the tightest binding by molecular docking analysis. Conclusion Our study indicated the underlying protective effect of Xuebijing injection on COVID-19, especially on COVID19-induced cardiac dysfunction, which provided the theoretical basis for exploring the potential protective mechanism of Xuebijing injection on COVID19-induced cardiac dysfunction.

Revealing the efficacy-toxicity relationship of Fuzi in treating rheumatoid arthritis by systems pharmacology

“…To screen the potential bioactive compounds from Fuzi, two important parameters including oral bioavailability (OB) and drug-likeness (DL) that are associated with drug absorption, distribution, metabolism, and excretion were used. The threshold for screening bioactive compounds was set as OB ≥ 30 and DL ≥ 0.18 17 . Because some compounds that did not pass the threshold might show significant pharmacological effects as well, compounds that were reported to exhibit strong pharmacological effects yet not meet the threshold of OB or DL were also used.…”

Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications

“…Network-based pharmacology to explore the molecular targets of the action of Wenxin Keli (WXKL) in the treatment of atrial fibrillation, it was found that these targets were closely related to inflammatory response, oxidative stress response, and immune regulation, and CCL2 was one of the main targets of its action ( 157 ). Bioinformatics analysis suggests that hemiphilin injection may exert a potential protective effect against neocoronary pneumonia, especially COVID19-induced cardiac insufficiency, by targeting seven Hub genes, including CCL2 and CXCL8, to inhibit oxidative stress, prevent atherosclerotic plaque formation, and suppress inflammation and apoptosis ( 158 ).…”

A review on computational approaches that support the researches on traditional Chinese medicines (TCM) against COVID-19

“…He et al . identified the therapeutic effect of Xuebijing injection on COVID-19-induced cardiac dysfunction using bioinformatics analysis ( He et al, 2021 ). Xuebijing injection indicated oxidative stress inhibition, atherosclerotic plaque prevention, inflammatory repression and apoptosis by targeting 7 central hub genes including CCL2, CXCL8, FOS, IFNB1, IL-1A, IL-1B, SERPINE1 that have protective mechanism on COVID-19-induced cardiac dysfunction.…”